HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival

Molecular Diagnosis

Volumn 5, Issue 3, 2000, Pages 199-207

  Kakar, Sanjay ^a   Puangsuvan, Nick ^a   Stevens, Jane M ^a   Serenas, Romualda ^a   Mangan, George ^a   Sahai, Shalini ^a   Mihalov, Michael L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Herceptin; Prognosis

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CORRELATION FUNCTION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE NEU; PROGNOSIS;

EID: 0033785293     PISSN: 10848592     EISSN: None     Source Type: Journal    
DOI: 10.1054/modi.2000.16690     Document Type: Article

References (32)

1. Her-2/neu testing comes of age
2. HER-2/neu gene and protein in breast cancer
3. Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer
4. Her-2/neu expression in node negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease
5. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB loverexpression, and Her-2 gene amplification detected by fluorescence in situ hybridization in breast cancer
6. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
7. C-erbB-2 oncoprotein expression versus internal mammary lymph node metastasis as additional prognostic factors in patients with axillary lymph node-positive breast cancer
8. Prognostic value of c-erbB-2 overexpression in axillary lymph node-positive breast cancer: Results from a randomized adjuvant treatment protocol
9. Detection and quantitation of Her-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
10. Adjuvant therapy of node negative breast cancer
11. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
12. Phase 2 study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER-2/neu monoclonal antibody plus cisplatin in patients with Her-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
13. Recombinant humanized anti-Her-2/neu antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against Her-2/neu overexpressing human breast cancer xenografts
14. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis
15. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
16. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastasis
17. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
18. Addition of Herceptin (humanized anti HER2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (HER+/MBC) markedly increases anticancer activity: A randomized, multinational controlled phase III trial
19. C-erb B-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer
20. p53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
21. Prognostic significance of HER-2/neu oncoprotein expression in node positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy
22. Sensitivity of Her-2/neu antibodies in archival samples: Potential source of error in immunohistochemical studies of oncogene expression
23. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
24. Comparison of fluorescent in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
25. High correlation between ERBB2 amplification detected by FISH and gene overexpression detected by immunohistochemistry in breast cancers
26. HER-2/neu oncogene overexpression: Comparison of immunohistochemistry with fluorescent in situ hybridization assay
27. Fluorescent in situ hybridization vs immunohistochemistry for determination of Her-2/neu status in breast cancer
28. C-erbB2 immunostaining: Problems with interpretation
29. Increased HER2 with US Food and Drug Administration-approved antibody
30. Cardiotoxicity in patients receiving transtuzumab (Herceptin): Primary toxicity, synergistic or sequential stress, or surveillance artifact?
31. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement
32. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: A multicenter portability study